Personalis, Inc. PSNL stock is up in Tuesday’s premarket session after the company received Medicare coverage for its NeXT ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company’s NeXT Personal molecular residual disease (MRD) test for ...

Personalis shares rose after the company received Medicare coverage for its NeXT Personal molecular residual disease test for surveillance of patients with Stage I to III non-small cell lung cancer.

Investing.com -- Personalis Inc (NASDAQ:PSNL) stock jumped 9.3% Tuesday after the precision oncology company announced Medicare coverage for its NeXT Personal molecular residual disease test for ...

Evaluating lung cancer clinical characteristics and tumor subtypes using cell-free DNA fragmentomes. A retrospective study of induction immunochemotherapy followed by definitive chemoradiotherapy and ...

NCCN's newly updated NSCLC guidelines add sevabertinib as a treatment option and datopotamab deruxtecan-dlink a potential preferred option.

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

Examination of post-radiation survey data from the navigator-assisted hypofractionation (NAVAH) phase I trial in African-American prostate cancer patients. Multivariable logistic regression analysis ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung cancers are non-small cell lung cancers, in which tumor cells are larger and ...